Loxapine Capsule
NDC Package 0591-0372-77
Package Information
Loxapine capsules is loxapine is used to treat certain mental/mood disorders (such as schizophrenia). This formulation utilizes a capsule delivery system. Marketed by Actavis Pharma, Inc., this product is identified by NDC 0591-0372 and is authorized under FDA application ANDA072062.
Identification & Billing
- RxCUI: 311385 - loxapine succinate 25 MG Oral Capsule
- RxCUI: 311385 - loxapine 25 MG Oral Capsule
- RxCUI: 311385 - loxapine 25 MG (as loxapine succinate 34 MG) Oral Capsule
- RxCUI: 311386 - loxapine succinate 5 MG Oral Capsule
- RxCUI: 311386 - loxapine 5 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0591 - Actavis Pharma, Inc.
- 0591-0372 - Loxapine
- 0591-0372-77 - 9805 CAPSULE in 1 CONTAINER
- 0591-0372 - Loxapine
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0591-0372). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0591-0372-77 identifies a specific commercial package of 9805 capsule in 1 container of Loxapine, a human prescription drug labeled by Actavis Pharma, Inc.. This capsule is formulated for oral use and contains loxapine succinate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Actavis Pharma, Inc. on June 15, 1988. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Loxapine is used to treat certain mental/mood disorders (such as schizophrenia). This medicine helps you to think more clearly, feel less nervous, and take part in everyday life. It can reduce aggression and the desire to hurt yourself/others. It may also help to decrease hallucinations (such as hearing/seeing things that are not there). Loxapine is a psychiatric medication (antipsychotic type) that works by helping to restore the balance of certain natural substances (such as dopamine) in the brain.
How is this Actavis Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00591037277. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.